Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasms 3Prostatic Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Ovarian Neoplasms 1Ototoxicity 1Heart Failure 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Cardiovascular Diseases 1Cardiotoxicity 1Atherosclerosis 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 387Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all
NCT03971019 2019-08-14

SBSBC

Peking Union Medical College Hospital

Phase 3 Unknown
314 enrolled
Breast

Breast Neoplasms

NCT00914017 2010-02-11

Statins and Breast Cancer Biomarkers

University of Vermont

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡